Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dova Pharmaceuticals Inc (DOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 417,642
  • Shares Outstanding, K 28,200
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,960 K
  • 36-Month Beta 0.71
  • Price/Sales 53.57
  • Price/Cash Flow N/A
  • Price/Book 4.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.72
  • Number of Estimates 4
  • High Estimate -0.66
  • Low Estimate -0.77
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.38 unch
on 12/17/18
16.22 -42.17%
on 12/12/18
-6.12 (-39.48%)
since 11/16/18
3-Month
9.38 unch
on 12/17/18
25.09 -62.61%
on 09/19/18
-15.10 (-61.68%)
since 09/17/18
52-Week
9.38 unch
on 12/17/18
37.00 -74.65%
on 02/20/18
-21.83 (-69.95%)
since 12/15/17

Most Recent Stories

More News
Dova Pharmaceuticals Announces Management Changes

Dr. David Zaccardelli appointed President and Chief Executive Officer

MLNT : 1.24 (+5.08%)
DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals (DOVA) Reports Q3 Loss, Tops Revenue Estimates

Dova Pharmaceuticals (DOVA) delivered earnings and revenue surprises of 15.85% and 10.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals: 3Q Earnings Snapshot

DURHAM, N.C. (AP) _ Dova Pharmaceuticals Inc. (DOVA) on Thursday reported a loss of $19.5 million in its third quarter.

DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals Reports Third Quarter 2018 Operating and Financial Results

Third quarter net product sales of $2.9 million from DOPTELET(avatrombopag); 335 cumulative unique prescribers from launch through September 30, 2018

DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals to Present at Upcoming Investor Conferences

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that the management team will present a company overview at four upcoming investor conferences:

DOVA : 9.51 (-35.79%)
Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kopin Corporation (NASDAQ:KOPN),...

KOPN : 1.45 (+2.84%)
MDCA : 2.95 (+1.72%)
REV : 24.43 (-2.08%)
IMMY : 5.66 (-2.92%)
DOVA : 9.51 (-35.79%)
NERV : 7.46 (-4.85%)
CORRECTING and REPLACING - Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET(R) (Avatrombopag)

In a release issued under the same headline earlier today by Dova Pharmaceuticals, Inc. ("Dova") (NASDAQ: DOVA), please note that the quote by Mark McKenna in the fifth paragraph has been updated.

DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET(R) (Avatrombopag)

Dova Pharmaceuticals, Inc. ("Dova") (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need,...

DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals to Present at Upcoming Investor Conferences

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences in New York:

DOVA : 9.51 (-35.79%)
Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today...

DOVA : 9.51 (-35.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

See More Share

Trade DOVA with:

Business Summary

Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 15.66
1st Resistance Point 15.23
Last Price 9.51
1st Support Level 14.46
2nd Support Level 14.12

See More

52-Week High 37.00
Fibonacci 61.8% 26.45
Fibonacci 50% 23.19
Fibonacci 38.2% 19.93
Last Price 9.51
52-Week Low 9.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar